Fierce Pharma May 10, 2024
After years of missteps in developing and commercializing its coronavirus shot, Novavax is turning to one of the biopharma industry’s most experienced vaccine companies to help salvage its COVID efforts: Sanofi.
The French Big Pharma will partner with the struggling Maryland biotech to co-commercialize its COVID-19 jab Nuvaxovid and develop combination vaccines.
In all, Novavax will receive $500 million up front, plus up to $700 million in potential development, regulatory and launch milestones plus tiered royalties. As part of the arrangement, Sanofi is taking a 4.9% equity position in Novavax.
Sanofi will book sales for Nuvaxovid at the start of next year. The French company’s vaccine legacy includes developing, manufacturing and commercializing shots worldwide to protect against polio, rabies, meningitis...
Today's Sponsors
Today's Sponsor